ArticleBioinformatics and biology insights2015
Antigenic Determinants of Possible Vaccine Escape by Porcine Circovirus Subtype 2b Viruses.
Article in Bioinformatics and biology insights, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Determining the dynamics of maternally derived antibodies in piglets prior to vaccination against porcine circovirus type 2.The Journal of veterinary medical science · 2026Article
- A porcine circovirus type 2d-based virus-like particle subunit vaccine effectively protects pigs against homologous challenge.Frontiers in microbiology · 2026Article
- Molecular Epidemic Characteristics and Genetic Evolution of Porcine Circovirus Type 2 in Henan, China.Veterinary sciences · 2025Article
- The Decade of Porcine Circovirus Type 2 (PCV2) in Thailand: Phylodynamic and Molecular Epidemiology.Transboundary and emerging diseases · 2025Article
- Epidemiological Investigation and Genetic Analysis of Duck Circovirus in Korea from 2013 to 2022.Animals : an open access journal from MDPI · 2024Article
- Trans-replicase helper activity of porcine circoviruses promotes the synergistic replication of torque teno virus.Frontiers in microbiology · 2024Article
- Co-circulation and genetic characteristics of porcine circoviruses in postweaning multisystemic wasting syndrome cases in commercial swine farms.Virusdisease · 2023Article
- Molecular genotypic analysis of porcine circovirus type 2 reveals the predominance of PCV2d in Vietnam (2018-2020) and the association between PCV2h, the recombinant forms, and Vietnamese vaccines.Archives of virology · 2022Article
- Review
- A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines.Veterinary research · 2022Article
- Article
- Harnessing the Genetic Plasticity of Porcine Circovirus Type 2 to Target Suicidal Replication.Viruses · 2021Article
- One Dose of a Novel Vaccine Containing Two Genotypes of Porcine Circovirus (PCV2a and PCV2b) andVaccines · 2021Article
- Targeted Alteration of Antibody-Based Immunodominance Enhances the Heterosubtypic Immunity of an Experimental PCV2 Vaccine.Vaccines · 2020Article
- Truncated Rep protein of porcine circovirus 2 (PCV2) caused by a naturally occurring mutation reduced virus replication in PK15 cells.BMC veterinary research · 2019Article
- Efficacy of a Commercial PCV2a Vaccine with a Two-Dose Regimen Against PCV2d.Veterinary sciences · 2019Article
- Porcine Circovirus Type 2 (PCV2) Vaccines in the Context of Current Molecular Epidemiology.Viruses · 2017Review
- Global Status ofAdvances in virology · 2017Review
- Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: A large scale epidemiological study.Scientific reports · 2016Article
- A Computationally Designed Serological Assay for Porcine Epidemic Diarrhea Virus.Journal of clinical microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently available commercial vaccines against porcine circovirus strain 2 (PCV2) solely target the PCV2a genotype. While PCV2 vaccines are highly effective in preventing clinical signs, PCV2b has dominated over the PCV2a genotype in prevalence, corresponding with the introduction of PCV2a vaccines. A recently emerged PCV2b recombinant with an additional amino acid in the capsid protein, designated the mutant PCV2b (mPCV2b), is cause for concern due to its increased virulence and rapid spread. The accumulation of recent evidence for the increased genetic diversity in PCV2 suggests that current vaccines against PCV2a may be inducing selection pressure and driving viral evolution. In this study, the hypothesis that differences in key immune epitopes between the PCV2a vaccine strains, a classical PCV2b strain called PCV2b 41513 obtained from a vaccine-failure case, and mPCV2b strains could promote vaccine escape was tested using immuno-informatic tools. In the major viral proteins, 9 of the 18 predicted swine leukocyte antigens (SLA) class-I epitopes, 8 of the 22 predicted SLA class-II epitopes, and 7 of the 25 predicted B cell epitopes varied between the vaccine and field strains. A majority of the substitutions in both the T- and B-cell epitopes were located in the capsid protein. Some B- and T-cell epitopes that were identified as immunogenic in the vaccine strain were not identified as epitopes in the field strains, indicating a subtle shift in the antigenic profile of the field strains. Several nonconserved epitopes had both predicted B- and T-cell functions. Therefore, substitutions in the dual epitopes could affect both arms of the immune response simultaneously, causing immune escape. Our findings support further rational design of PCV2 vaccines to increase the current threshold of protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.